Literature DB >> 30180270

NLR Family Pyrin Domain-Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice.

Maria Eugenia Inzaugarat1, Casey D Johnson2, Theresa Maria Holtmann1, Matthew D McGeough2, Christian Trautwein1, Bettina G Papouchado3, Robert Schwabe4, Hal M Hoffman2, Alexander Wree1,2, Ariel E Feldstein2.   

Abstract

The NLR family pyrin domain-containing 3 (NLRP3) inflammasome plays an important role in liver fibrosis (LF) development. However, the mechanisms involved in NLRP3-induced fibrosis are unclear. Our aim was to test the hypothesis that the NLRP3 inflammasome in hepatic stellate cells (HSCs) can directly regulate their activation and contribute to LF. Primary HSCs isolated from wild-type (WT), Nlrp3-/- , or Nlrp3L351PneoR knock-in crossed to inducible (estrogen receptor Cre-CreT) mice were incubated with lipopolysaccharide (LPS) and adenosine triphosphate (ATP), or 4OH-tamoxifen, respectively. HSC-specific Nlrp3L351P knock-in mice were generated by crossing transgenic mice expressing lecithin retinol acyltransferase (Lrat)-driven Cre and maintained on standard rodent chow for 6 months. Mice were then sacrificed; liver tissue and serum were harvested. Nlrp3 inflammasome activation along with HSC phenotype and fibrosis were assessed by RT-PCR, western blotting, fluorescence-activated cell sorting (FACS), enzyme-linked immunosorbent assay, immunofluorescence (IF), and immunohistochemistry (IHC). Stimulated WT HSCs displayed increased levels of NLRP3 inflammasome-induced reactive oxygen species (ROS) production and cathepsin B activity, accompanied by an up-regulation of mRNA and protein levels of fibrotic makers, an effect abrogated in Nlrp3-/- HSCs. Nlrp3L351P CreT HSCs also showed elevated mRNA and protein expression of fibrotic markers 24 hours after inflammasome activation induced with 4-hydroxytamoxifen (4OHT). Protein and mRNA expression levels of fibrotic markers were also found to be increased in isolated HSCs and whole liver tissue from Nlrp3L351P Lrat Cre mice compared to WT. Liver sections from 24-week-old NlrpL351P Lrat Cre mice showed fibrotic changes with increased alpha smooth muscle actin (αSMA) and desmin-positive cells and collagen deposition, independent of inflammatory infiltrates; these changes were also observed after LPS challenge in 8-week-old NlrpL351P Lrat Cre mice.
Conclusion: Our results highlight a direct role for the NLRP3 inflammasome in the activation of HSCs directly triggering LF.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2019        PMID: 30180270      PMCID: PMC6351190          DOI: 10.1002/hep.30252

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  34 in total

1.  Absence of hepatic stellate cell retinoid lipid droplets does not enhance hepatic fibrosis but decreases hepatic carcinogenesis.

Authors:  Johannes Kluwe; Nuttaporn Wongsiriroj; Juliane S Troeger; Geum-Youn Gwak; Dianne H Dapito; Jean-Philippe Pradere; Hongfeng Jiang; Maham Siddiqi; Roseann Piantedosi; Sheila M O'Byrne; William S Blaner; Robert F Schwabe
Journal:  Gut       Date:  2011-01-27       Impact factor: 23.059

Review 2.  Inflammasomes in health and disease.

Authors:  Till Strowig; Jorge Henao-Mejia; Eran Elinav; Richard Flavell
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

3.  Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice.

Authors:  Kouichi Miura; Yuzo Kodama; Sayaka Inokuchi; Bernd Schnabl; Tomonori Aoyama; Hirohide Ohnishi; Jerrold M Olefsky; David A Brenner; Ekihiro Seki
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

Review 4.  Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies.

Authors:  Jing-Ting Li; Zhang-Xiu Liao; Jie Ping; Dan Xu; Hui Wang
Journal:  J Gastroenterol       Date:  2008-07-04       Impact factor: 7.527

5.  A new method for removal of mononuclear phagocytes from heterogeneous cell populations in vitro, using the liposome-mediated macrophage 'suicide' technique.

Authors:  I Claassen; N Van Rooijen; E Claassen
Journal:  J Immunol Methods       Date:  1990-12-05       Impact factor: 2.303

6.  Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice.

Authors:  Yehuda Kamari; Aviv Shaish; Einav Vax; Shay Shemesh; Michal Kandel-Kfir; Yaron Arbel; Sarita Olteanu; Iris Barshack; Shahar Dotan; Elana Voronov; Charles A Dinarello; Ron N Apte; Dror Harats
Journal:  J Hepatol       Date:  2011-02-24       Impact factor: 25.083

7.  Inflammasome-mediated regulation of hepatic stellate cells.

Authors:  Azuma Watanabe; Muhammad Adnan Sohail; Dawidson Assis Gomes; Ardeshir Hashmi; Jun Nagata; Fayyaz Shiraz Sutterwala; Shamail Mahmood; Muhammad Nauman Jhandier; Yan Shi; Richard Anthony Flavell; Wajahat Zafar Mehal
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-09       Impact factor: 4.052

8.  Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo.

Authors:  Shan-Shan Zhan; Joy X Jiang; Jian Wu; Charles Halsted; Scott L Friedman; Mark A Zern; Natalie J Torok
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425

9.  Interleukin-1 participates in the progression from liver injury to fibrosis.

Authors:  Roben G Gieling; Karen Wallace; Yuan-Ping Han
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-02       Impact factor: 4.052

10.  Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity.

Authors:  Susannah D Brydges; James L Mueller; Matthew D McGeough; Carla A Pena; Amirhossein Misaghi; Chhavi Gandhi; Chris D Putnam; David L Boyle; Gary S Firestein; Anthony A Horner; Pejman Soroosh; Wendy T Watford; John J O'Shea; Daniel L Kastner; Hal M Hoffman
Journal:  Immunity       Date:  2009-06-04       Impact factor: 31.745

View more
  32 in total

1.  The peripheral CB1 receptor antagonist JD5037 attenuates liver fibrosis via a CB1 receptor/β-arrestin1/Akt pathway.

Authors:  Siwei Tan; Huiling Liu; Bilun Ke; Jie Jiang; Bin Wu
Journal:  Br J Pharmacol       Date:  2020-03-03       Impact factor: 8.739

Review 2.  Purinergic signaling in hepatic disease.

Authors:  E Velázquez-Miranda; M Díaz-Muñoz; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2019-10-01       Impact factor: 3.765

3.  Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH.

Authors:  Shashi Bala; Michal Ganz; Mrigya Babuta; Yuan Zhuang; Timea Csak; Charles D Calenda; Gyongyi Szabo
Journal:  Lab Invest       Date:  2021-08-27       Impact factor: 5.502

Review 4.  Hepatic Stellate Cell-Immune Interactions in NASH.

Authors:  James K Carter; Scott L Friedman
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

5.  CHI3L1 alleviate acute liver injury by inhibiting Th1 cells differentiation through STAT3 signaling pathway.

Authors:  Shaopeng Zhang; Xinzheng Dai; Yong Shi; Xiaowen Zhu; Yongjiu Dai; Xiaofeng Qian; Jian Gu
Journal:  Ann Transl Med       Date:  2021-04

Review 6.  Inflammasome as an Effective Platform for Fibrosis Therapy.

Authors:  Ting-Ting Chen; Feng Xiao; Nan Li; Shan Shan; Meng Qi; Zi-Ying Wang; Sheng-Nan Zhang; Wei Wei; Wu-Yi Sun
Journal:  J Inflamm Res       Date:  2021-04-20

7.  Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome.

Authors:  Hyun Young Kim; Young Jae Choi; Sang Kyum Kim; Hyunsung Kim; Dae Won Jun; Kyungrok Yoon; Nayoun Kim; Jungwook Hwang; Young-Mi Kim; Sung Chul Lim; Keon Wook Kang
Journal:  Commun Biol       Date:  2021-06-30

8.  Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.

Authors:  Susanne Gaul; Aleksandra Leszczynska; Fernando Alegre; Benedikt Kaufmann; Casey D Johnson; Leon A Adams; Alexander Wree; Georg Damm; Daniel Seehofer; Carolina J Calvente; Davide Povero; Tatiana Kisseleva; Akiko Eguchi; Matthew D McGeough; Hal M Hoffman; Pablo Pelegrin; Ulrich Laufs; Ariel E Feldstein
Journal:  J Hepatol       Date:  2020-08-04       Impact factor: 25.083

Review 9.  Inflammasomes and Fibrosis.

Authors:  Wen-Juan Zhang; Shu-Juan Chen; Shun-Chang Zhou; Su-Zhen Wu; Hui Wang
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

10.  Oridonin ameliorates carbon tetrachloride-induced liver fibrosis in mice through inhibition of the NLRP3 inflammasome.

Authors:  Dong Liu; Hailong Qin; Bixian Yang; Bin Du; Xuelin Yun
Journal:  Drug Dev Res       Date:  2020-03-26       Impact factor: 4.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.